Navigation Links
CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
Date:9/18/2012

DURHAM, N.C., Sept. 18, 2012 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting. Lasmiditan is a novel therapy for acute migraine and will initially be developed to address major unmet needs in two patient populations who are poorly served by currently available therapies:  1) patients with risk factors for cardiovascular disease and those with diagnosed cardiovascular disease and 2) patients who have not had adequate efficacy from triptans.  The development program will be confirmed via the Special Protocol Assessment process.

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans.

CoLucid has further evaluated lasmiditan's cardiovascular profile by recently completing a Thorough QT/QTc study (TQT) titled COL MIG-105: A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Re-polarization Duration as well as other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) with those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects.  The statistical evaluation of the primary variable revealed that lasmiditan caused no significant QT prolongation either at 100 mg (the putative therapeutic dose) or at 400 m
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... , Sanofi and Regeneron will host an IR Thematic ... Tuesday, September 2, 2014 , Baird 2014 Healthcare ... 3, 2014 , Citi,s 9 th Annual ... September 4, 2014 , Morgan Stanley Global Healthcare ...
(Date:8/19/2014)... Colo. , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), ... rd Annual Meeting of the American Academy ... Acute Care Surgery in Philadelphia, Pennsylvania ... 2014.  The presentation will report results from a ...
(Date:8/19/2014)... August 19, 2014 According to ... (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast, 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
... China , July 9 /PRNewswire-Asia-FirstCall/ -- ... or the "Company"), a,developer, manufacturer and distributor of ... announced,that on July 8, 2010 , the ... Red Star Forest Bureau of Heilongjiang Province ...
... ATHENS, Greece , July 9 The companies ... and translator of the Greek language version of the GeneMedRx ... the program will include hundreds of drugs used exclusively in ... Greek language graphical user interface. Both the English and Greek ...
Cached Medicine Technology:Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng 2Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng 3Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng 4Medigene Appointed Exclusive Greek Licensee for GeneMedRx Personalized Prescribing Software 2
(Date:8/19/2014)... published in this week,s JAMA highlights the ... when considering how to treat patients. Written by Robert ... and chair of pediatrics at Boston University School of ... , the editorial examines results of a study published ... example of how doctors can often over-emphasize certain types ...
(Date:8/19/2014)... Recently, UWDress.com, a professional company of women’s ... plus size formal evening dresses . Additionally, the firm ... outfits. At the moment, all of them can be ordered ... will be valid until August 27, 2014. , The ... top designers believe that women of all shapes can be ...
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey ... again teaming up during The Barclays at The Ridgewood ... Challenge, and Horizon BCBSNJ will be getting spectators into the ... their own. , Horizon BCBSNJ, the official health care sponsor ... donation to the New Jersey Golf Foundation, an organization that ...
(Date:8/19/2014)... ME (PRWEB) August 19, 2014 Drews Dental ... J. Drews, D.D.S., to vice president of the Maine Dental ... MDA for three years, Dr. Drews has now been sworn ... forward to serving his term as vice president and being ... as well as the First District Caucus in 2015. He ...
(Date:8/19/2014)... smoke during their stay and could use this time as ... smoke-free after returning home. Now a study published in ... program that increased the proportion of hospitalized smokers who successfully ... The system used interactive voice response technology automated telephone ... months after smokers left the hospital. , "Most ...
Breaking Medicine News(10 mins):Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2Health News:Cheap Plus Size Formal Evening Dresses Announced By UWDress.com 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Dr. Drews Elected VP of Maine Dental Association 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2
... , , , ... the U.S. Food and Drug Administration (FDA) has approved a 3000 ... factor (recombinant). The new vial size offers greater convenience for ... , The 3000 IU vial may eliminate the need ...
... , NEW YORK, Aug. 7 President Bill ... Yancy, president of the American Heart Association and Dr. ... the Fourth Annual Healthy Schools Program Forum in New York to honor 114 ... to learn and staff to work. , , "As kids ...
... , ARDEE, Ireland, Aug. 7 /PRNewswire-Firstcall/ ... its results for the quarter ended June 30, 2009. Revenue in ... over the prior year quarter. The primary drivers of the increase ... and ESTRACE Cream which were partially offset by net sales declines ...
... , LOS ANGELES, Aug. 7 "August marks ... comments Susan, mother of five and teacher who recalls living with ... next you,d have thought Satan walked through the door." , ... *(Photo Caption/Cutline: Mother with drug-free daughter, a Narconon graduate.) , ...
... ... RN, MBA, CMRP, as vice president for consulting. , ... St. Louis, MO (Vocus) -- Navvis & ... consulting. Cleveland brings to the firm and its clients extensive experience and expertise in ...
... Carnegie Mellon University have developed an analytical technique ... to complex disease syndromes such as diabetes, asthma ... and molecular traits. , Rather than searching one ... a particular symptom or trait, as in ...
Cached Medicine News:Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 2Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 3Health News:FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant) 4Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 2Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 3Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 4Health News:More Than 100 Healthy Schools Honored by the Alliance for a Healthier Generation 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Mother & Daughter Celebrate Victory Over 'Meth' 2Health News:Cleveland Joins Navvis & Company 2Health News:Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
... full protection is necessary, the Two-Piece ... add to your comfort through more ... greater flexibility. The vest comes with ... hanging loops as well as an ...
Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
... unique velcro design apron has ... support and comfort. Shoulder pads ... flaps aid in relieving weight ... fit is attained by varying ...
Medicine Products: